|
1
|
Harting K and Knöll B: SIRT2-mediated
protein deacetylation: An emerging key regulator in brain
physiology and pathology. Eur J Cell Biol. 89:262–269. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sherman JM, Stone EM, FreemanCook LL,
Brachmann CB, Boeke JD and Pillus L: The conserved core of a human
SIR2 homologue functions in yeast silencing. Mol Biol Cell.
10:3045–3059. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Blander G and Guarente L: The Sir2 family
of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Michan S and Sinclair D: Sirtuins in
mammals: Insights into their biological function. Biochem J.
404:1–13. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Taylor DM, Maxwell MM, LuthiCarter R and
Kazantsev AG: Biological and potential therapeutic roles of sirtuin
deacetylases. Cell Mol Life Sci. 65:4000–4018. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McGuinness D, McGuinness DH, McCaul JA and
Shiels PG: Sirtuins, bioageing, and cancer. J Aging Res.
2011:2357542011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Haberland M, Montgomery RL and Olson EN:
The many roles of histone deacetylases in development and
physiology: Implications for disease and therapy. Nat Rev Genet.
10:32–42. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Finkel T, Deng CX and Mostoslavsky R:
Recent progress in the biology and physiology of sirtuins. Nature.
460:587–591. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haigis MC and Sinclair DA: Mammalian
sirtuins: Biological insights and disease relevance. Annu Rev
Pathol. 5:253–295. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miremadi A, Oestergaard MZ, Pharoah PD and
Caldas C: Cancer genetics of epigenetic genes. Hum Mol Genet.
16:R28–R49. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jang KY, Hwang SH, Kwon KS, Kim KR, Choi
HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, et al: SIRT1
expression is associated with poor prognosis of diffuse large
B-cell lymphoma. Am J Surg Pathol. 32:1523–1531. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bradbury CA, Khanim FL, Hayden R, Bunce
CM, White DA, Drayson MT, Craddock C and Turner BM: Histone
deacetylases in acute myeloid leukemia show a distinctive pattern
of expression that changes selectively in response to deacetylase
inhibitors. Leukemia. 19:1751–1759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huffman DM, Grizzle WE, Bamman MM, Kim JS,
Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated
in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McGlynn L, Curle J, Edwards J and Shies P:
Evaluating the role of sirtuins 5,6 & 7 in breast cancer.
Cancer Res. 69:30342009. View Article : Google Scholar
|
|
15
|
Firestein R, Blander G, Michan S,
Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S,
de Cabo R, Fuchs C, et al: The SIRT1 deacetylase suppresses
intestinal tumorigenesis and colon cancer growth. PLoS One.
3:e20202008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song NY and Surh YJ: Janus-faced role of
SIRT1 in tumorigenesis. Ann N Y Acad Sci. 1271:10–19. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang CJ, Hsu CC, Yung MC, Chen KY, Tzao
C, Wu WF, Chou HY, Lee YY, Lu KH, Chiou SH, et al: Enhanced
radiosensitivity and radiation-induced apoptosis in glioma
CD133-positive cells by knockdown of SirT1 expression. Biochem
Biophys Res Commun. 380:236–242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem cells in
glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lages E, Guttin A, ElAtifi M, Ramus C,
Ipas H, Dupré I, Rolland D, Salon C, Godfraind C, de Fraipont F, et
al: MicroRNA and target protein patterns reveal physiopathological
features of glioma subtypes. PLoS One. 6:e206002011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang RH, Sengupta K, Li C, Kim HS, Cao L,
Xiao C, Kim S, Xu X, Zheng Y, Chilton B, et al: Impaired DNA damage
response, genome instability, and tumorigenesis in SIRT1 mutant
mice. Cancer Cell. 14:312–323. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qu Y, Zhang J, Wu S, Li B, Liu S and Cheng
J: SIRT1 promotes proliferation and inhibits apoptosis of human
malignant glioma cell lines. Neurosci Lett. 525:168–172. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Deng CX: SIRT1, Is it a tumor promoter or
tumor suppressor? Int J Biol Sci. 5:147–152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamakuchi M: MicroRNA regulation of SIRT1.
Front Physiol. 3:682012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao J, Wang WY, Mao YW, Graff J, Guan JS,
Pan L, Mak G, Kim D, Su SC and Tsai LH: A novel pathway regulates
memory and plasticity via SIRT1 and miR-134. Nature. 466:1105–1109.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamakuchi M and Lowenstein C J: MiR-34,
SIRT1 and p53: the feedback loop. Cell Cycle. 8:712–715. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ciafrè SA, Galardi S, Mangiola A, Ferracin
M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM and Farace MG:
Extensive modulation of a set of microRNAs in primary glioblastoma.
Biochem Biophys Res Commun. 334:1351–1358. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jia Z, Wang K, Zhang A, Wang G, Kang C,
Han L and Pu P: miR-19a and miR-19b overexpression in gliomas.
Pathol Oncol Res. 19:847–853. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Conti A, Aguennouz M, La Torre D,
Tomasello C, Cardali S, Angileri FF, Maio F, Cama A, Germanò A,
Vita G and Tomasello F: miR-21 and 221 upregulation and miR-181b
downregulation in human grade II–IV astrocytic tumors. J
Neurooncol. 93:325–332. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peltier HJ and Latham GJ: Normalization of
microRNA expression levels in quantitative RT-PCR assays:
Identification of suitable reference RNA targets in normal and
cancerous human solid tissues. RNA. 14:844–52. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song J, Bai Z, Han W, Zhang J, Meng H, Bi
J, Ma X, Han S and Zhang Z: Identification of suitable reference
genes for qPCR analysis of serum microRNA in gastric cancer
patients. Dig Dis Sci. 57:897–904. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M
and Rajewsky N: Combinatorial microRNA target predictions. Nat
Genet. 37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nakahata Y, Sahar S, Astarita G, Kaluzova
M and Sassone-Corsi P: Circadian control of the NAD+ salvage
pathway by CLOCK-SIRT1. Science. 324:654–657. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vaquero A, Scher M, Lee D,
ErdjumentBromage H, Tempst P and Reinberg D: Human SirT1 interacts
with histone H1 and promotes formation of facultative
heterochromatin. Mol Cell. 16:93–105. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pruitt K, Zinn RL, Ohm JE, McGarvey KM,
Kang SH, Watkins DN, Herman JG and Baylin SB: Inhibition of SIRT1
reactivates silenced cancer genes without loss of promoter DNA
hypermethylation. PLoS Genet. 2:e402006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu T, Liu PY and Marshall GM: The
critical role of the class III histone deacetylase SIRT1 in cancer.
Cancer Res. 69:1702–1705. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saunders LR and Verdin E: Sirtuins:
Critical regulators at the crossroads between cancer and aging.
Oncogene. 26:5489–5504. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vaziri H, Dessain SK, Ng Eaton E, Imai SI,
Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2 (SIRT1)
functions as an NAD-dependent p53 deacetylase. Cell. 107:149–159.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bouras T, Fu M, Sauve AA, Wang F, Quong
AA, Perkins ND, Hay RT, Gu W and Pestell RG: SIRT1 deacetylation
and repression of p300 involves lysine residues 1020/1024 within
the cell cycle regulatory domain1. J Biol Chem. 280:10264–10276.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Muth V, Nadaud S, Grummt I and Voit R:
Acetylation of TAF(I)68, a subunit of TIF-IB/SL1, activates RNA
polymerase I transcription. EMBO J. 20:1353–1362. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Placone AL, Quiñones-Hinojosa A and
Searson PC: The role of astrocytes in the progression of brain
cancer: Complicating the picture of the tumor microenvironment.
Tumour Biol. 2015.(Epub ahead of print). PubMed/NCBI
|
|
42
|
Dutta KK, Zhong Y, Liu YT, Yamada T,
Akatsuka S, Hu Q, Yoshihara M, Ohara H, Takehashi M, Shinohara T,
et al: Association of microRNA-34a overexpression with
proliferation is cell type-dependent. Cancer Sci. 98:1845–1852.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lodygin D, Tarasov V, Epanchintsev A,
Berking C, Knyazeva T, Körner H, Knyazev P, Diebold J and Hermeking
H: Inactivation of miR-34a by aberrant CpG methylation in multiple
types of cancer. Cell Cycle. 7:2591–600. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bommer GT, Gerin I, Feng Y, Kaczorowski
AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al:
p53-mediated activation of miRNA34 candidate tumor-suppressor
genes. Curr Biol. 17:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chang TC, Wentzel EA, Kent OA,
Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M,
Ferlito M, Lowenstein CJ, et al: Transactivation of miR-34a by p53
broadly influences gene expression and promotes apoptosis. Mol
Cell. 26:745–752. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
He L, He X, Lim LP, de Stanchina E, Xuan
Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tarasov V, Jung P, Verdoodt B, Lodygin D,
Epanchintsev A, Menssen A, Meister G and Hermeking H: Differential
regulation of microRNAs by p53 revealed by massively parallel
sequencing: miR-34a is a p53 target that induces apoptosis and
G1-arrest. Cell Cycle. 6:1586–1593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fujita Y, Kojima K, Hamada N, Ohhashi R,
Akao Y, Nozawa Y, Deguchi T and Ito M: Effects of miR-34a on cell
growth and chemoresistance in prostate cancer PC3 cells. Biochem
Biophys Res Commun. 377:114–119. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pogribny IP, Muskhelishvili L, Tryndyak VP
and Beland FA: The tumor-promoting activity of
2-acetylaminofluorene is associated with disruption of the p53
signalIng pathway and the balance between apoptosis and cell
proliferation. Toxicol Appl Pharmacol. 235:305–311. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kojima K, Fujita Y, Nozawa Y, Deguchi T
and Ito M: MiR-34a attenuates paclitaxel-resistance of
hormone-refractory prostate cancer PC3 cells through direct and
indirect mechanisms. Prostate. 70:1501–1512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Luan S, Sun L and Huang F: MicroRNA-34a: A
novel tumor suppressor in p53-mutant glioma cell line U251. Arch
Med Res. 41:67–74. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pramanik D, Campbell NR, Karikari C,
Chivukula R, Kent OA, Mendell JT and Maitra A: Restitution of tumor
suppressor microRNAs using a systemic nanovector inhibits
pancreatic cancer growth in mice. Mol Cancer Ther. 10:1470–1480.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang S, Hao J, Xie F, Hu X, Liu C, Tong
J, Zhou J, Wu J and Shao C: Downregulation of miR-132 by promoter
methylation contributes to pancreatic cancer development.
Carcinogenensis. 32:1183–1189. 2011. View Article : Google Scholar
|
|
54
|
Menghini R, Casagrande V, Cardellini M,
Martelli E, Terrinoni A, Amati F, VasaNicotera M, Ippoliti A,
Novelli G, Melino G, et al: MicroRNA 217 modulates endothelial cell
senescence via silent information regulator 1. Circulation.
120:1524–1532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
vanRooij E: The art of microRNA research.
Circ Res. 108:219–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sarver AL and Subramanian S: Competing
endogenous RNA database. Bioinformation. 8:731–733. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kartha RV and Subramanian S: Competing
endogenous RNAs (ceRNAs): New entrants to the intricacies of gene
regulation. Front Genet. 5:82014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Karreth FA and Pandolfi PP: ceRNA
cross-talk in cancer: When ce-bling rivalries go awry. Cancer
Discov. 3:1113–1121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Vasudevan S: Posttranscriptional
upregulation by microRNAs. Wiley Interdiscip Rev RNA. 3:311–330.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lewis BP, Shih IH, JonesRhoades MW, Bartel
DP and Burge CB: Prediction of mammalian microRNA targets. Cell.
115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
ValinezhadOrang A, Safaralizadeh R and
Kazemzadeh-Bavili M: Mechanisms of miRNA-mediated gene regulation
from common downregulation to mRNA-specific upregulation. Int J
Genomics. 2014:9706072014.PubMed/NCBI
|
|
63
|
Fang Y and Nicholl MB: Sirtuin 1 in
malignant transformation: Friend or foe? Cancer Lett. 306:10–14.
2011. View Article : Google Scholar : PubMed/NCBI
|
